Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V1 and TRuE-V2 Phase 3 Results
Key Takeaways Two parallel phase 3 RCTs (TRuE-V1/V2) showed superiority vs vehicle on F-VASI at week 24, with continued gains […]
TRuE-V2
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V2 Phase 3 Results
Key Takeaways TRuE-V2 confirmed facial repigmentation superiority of ruxolitinib 1.5% cream versus vehicle at ~24 weeks, mirroring TRuE-V1. Continued treatment